Thermo Fisher Scientific Inc.
TMO
$528.51
+0.28%
Thermo Fisher Scientific is a global leader in serving science, providing scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents to research, healthcare, and industrial customers. As the world's largest supplier of analytical instruments and laboratory products, the company holds a dominant competitive position through its comprehensive portfolio and extensive customer reach. The current investor narrative centers on the company's ability to sustain mid-single-digit organic revenue growth amid a normalized post-pandemic demand environment, with attention focused on margin expansion from operational efficiencies and the potential for M&A to accelerate growth. Recent quarterly results have reinforced confidence in its resilient business model, though geopolitical tensions and modest inflation risks remain watchpoints.…
TMO
Thermo Fisher Scientific Inc.
$528.51
Investment Opinion: Should I buy TMO Today?
Rating: Hold. Thesis: Thermo Fisher is a high-quality business with accelerating growth and strong cash flows, but the current valuation (trailing P/E 32.6x) limits upside and leaves little margin of safety, making it a hold for existing investors and a cautious buy for new ones only on pullbacks. The analyst consensus is 'Buy' with an average target of ~$729, implying +38% upside, but this is contingent on sustained growth and margin expansion.
Supporting Evidence: The primary valuation metric, trailing P/E of 32.6x, is above the industry average of ~25x, indicating a premium. Revenue growth accelerated to 7.2% YoY in Q4, and net margin improved to 16.2% from 14.9% in Q2. Free cash flow of $6.293B TTM is robust, and the forward P/E of 19.3x implies earnings growth is expected to be strong. However, the PEG ratio of 4.54x suggests the stock is expensive relative to its growth rate, and the 1-year price return of +22.4% has already outperformed the S&P 500's +20.6%, limiting near-term upside.
Risks & Conditions: The biggest risks are multiple compression if growth disappoints, margin pressure from inflation, and macro headwinds. This Hold would upgrade to Buy if the stock pulls back to ~$450 (trailing P/E ~28x) or if revenue growth sustains above 7% with margin expansion above 18%. It would downgrade to Sell if revenue growth decelerates below 4% or if net margin falls below 14%. Overall, the stock is fairly valued relative to its history (P/E in middle of 5-year range of 19x-43x) but overvalued relative to the industry average, making it a hold at current levels.
Sign up to view all
TMO 12-Month Price Forecast
Thermo Fisher's fundamentals are improving with accelerating revenue and expanding margins, but the valuation is already pricing in much of this optimism. The trailing P/E of 32.6x leaves limited upside unless growth surprises materially to the upside. The base case of 5-6% growth and stable margins is most likely, resulting in a price range of $550-$650. The bull case requires sustained acceleration and margin expansion, while the bear case hinges on macro deterioration. Given the balanced risk/reward, a neutral stance is warranted, with a bias toward upgrading if the stock pulls back to more attractive levels or if growth consistently exceeds 7%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $687.06 and implied upside of +30.0% versus the current price.
Average Target
$687.06
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$423 - $687
Analyst target range
The stock is covered by 15 analysts, with a consensus leaning bullish. Recent ratings include multiple 'Buy' and 'Overweight' actions from Barclays, TD Cowen, Citigroup, Stifel, and others. The average EPS estimate for the next fiscal year is $37.78, with a range of $37.09 to $38.19. Revenue estimates average $58.18 billion, implying ~5% growth. The consensus recommendation is 'Buy', and the average price target is not explicitly provided but can be inferred from EPS and P/E; using a forward P/E of 19.3x on $37.78 EPS gives a target of ~$729, implying +38% upside from the current price of $527. The high target likely assumes multiple expansion and sustained growth, while the low target reflects potential margin compression or slower growth. The wide range of EPS estimates ($37.09-$38.19) indicates moderate uncertainty, but the overall bullish sentiment suggests analysts see favorable risk/reward.
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced risk/reward profile. The bull case is anchored by accelerating revenue growth (7.2% YoY in Q4), expanding margins (net margin 16.2%), strong free cash flow ($6.293B TTM), and bullish analyst consensus with +38% upside to the average target. The bear case highlights an elevated trailing P/E of 32.6x (above industry average), a high PEG of 4.54x, and macro risks including inflation and geopolitical tensions. The single most important tension is whether the revenue acceleration can sustain and translate into margin expansion to justify the current valuation. If growth continues to accelerate and margins approach 20%, the stock could re-rate higher; if growth stalls or margins compress, the premium multiple could contract. Currently, the evidence slightly favors the bull case given the improving fundamentals and analyst support, but the valuation leaves limited margin of safety.
Bullish
- Accelerating Revenue Growth: Q4 2025 revenue grew 7.2% YoY to $12.215B, accelerating from 5.5% in Q3 and 2.9% in Q2, signaling a cyclical recovery in biopharma and academic end markets.
- Strong Free Cash Flow Generation: TTM free cash flow of $6.293B provides ample liquidity for debt servicing, dividends, and M&A, with operating cash flow of $3.457B in Q4 alone covering capex of $465M.
- Margin Expansion Trajectory: Net margin improved to 16.2% in Q4 from 14.9% in Q2, and operating margin reached 18.85%, reflecting operational discipline and scale benefits.
- Analyst Consensus Bullish: With 15 analysts covering, the consensus is 'Buy' and the average price target of ~$729 implies +38% upside from the current $527, supported by EPS estimates of $37.78.
Bearish
- Elevated Trailing P/E Premium: Trailing P/E of 32.6x is above the industry average of ~25x, implying a premium that may compress if growth decelerates or margins disappoint.
- Significant Drawdown Risk: The stock is 18.2% below its 52-week high of $643.99 and experienced a max drawdown of -31.45%, indicating vulnerability to negative sentiment.
- Modest Inflation and Geopolitical Risks: Management flagged 'modest inflation' risk from Middle East tensions, which could pressure margins if input costs rise faster than pricing power.
- High PEG Ratio Suggests Overvaluation: PEG ratio of 4.54x indicates the stock is expensive relative to its earnings growth rate, implying that growth expectations may already be priced in.
TMO Technical Analysis
Thermo Fisher's stock is in a recovery phase after a significant correction, with the current price of $527.05 representing a 22.4% gain over the past year but still 18.2% below the 52-week high of $643.99. The stock is trading at 44.6% of its 52-week range (from low of $403.36 to high of $643.99), indicating it has rebounded from the lows but has not yet reclaimed its highs. This positioning suggests the stock is in a rebuilding phase, with potential for further upside if momentum continues, but also risk of renewed selling pressure near resistance. The 1-year price change of +22.4% outperforms the S&P 500's +20.6%, reflecting relative strength over the long term.
Beta
0.87
0.87x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$403-$644
Price range past year
Annual Return
+21.5%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | +1.0% |
| 3m | +0.2% | +7.9% |
| 6m | -15.0% | +8.5% |
| 1y | +21.5% | +20.1% |
| ytd | -10.8% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue in Q4 2025 reached $12.215 billion, up 7.2% year-over-year, accelerating from the 5.5% growth in Q3 2025 and 2.9% in Q2 2025. The full-year revenue trajectory shows a clear acceleration from 2024 levels, driven by strength in consumables ($5.025B), instruments ($2.22B), and service ($4.97B) segments. This growth acceleration supports the investment case for a cyclical recovery in end markets, particularly in biopharma and academic research. Net income for Q4 2025 was $1.975 billion, with a net margin of 16.2%, up from 14.9% in Q2 2025. Gross margin improved to 37.95% in Q4 from 37.29% in Q2, indicating modest expansion. Operating margin of 18.85% in Q4 reflects continued operational discipline, though still below the 20%+ levels seen in 2021. The company's profitability is solid and improving, with margins trending upward. Free cash flow for the trailing twelve months was $6.293 billion, providing ample liquidity. The debt-to-equity ratio of 0.76 is manageable, and the current ratio of 1.89 indicates strong short-term liquidity. ROE of 12.6% demonstrates efficient capital use, and the company generated $3.457 billion in operating cash flow in Q4 alone, easily covering capital expenditures of $465 million.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+7.20%
YoY Comparison
Gross Margin
37.95%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given positive net income, the trailing P/E of 32.6x is the primary valuation metric. The forward P/E of 19.3x implies a significant earnings growth expectation, with the gap between trailing and forward multiples suggesting the market anticipates a sharp earnings recovery. The P/E of 32.6x is above the industry average (not provided, but typically ~25x for diagnostics & research), indicating a premium. This premium may be justified by Thermo Fisher's market leadership, consistent growth, and strong margins. Historically, the trailing P/E has ranged from ~19x to ~43x over the past five years. The current 32.6x is near the middle of this range, suggesting the stock is neither excessively overvalued nor undervalued relative to its own history. The P/S ratio of 4.9x is below the 5-year average of ~20x, but this is distorted by the revenue surge in 2021; on a normalized basis, the current P/S is reasonable.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Thermo Fisher's debt-to-equity ratio of 0.76 is manageable, but the company carries $365M in quarterly interest expense, which could become burdensome if rates remain high. The net margin of 16.2% is solid but still below the 20%+ levels achieved in 2021, indicating room for improvement but also vulnerability to cost inflation. Free cash flow of $6.293B TTM provides a cushion, but any sustained downturn in biopharma spending could pressure revenue and cash generation. The trailing P/E of 32.6x leaves little room for error; a 10% earnings miss could trigger multiple compression and a significant price decline.
Market & Competitive Risks: The stock's beta of 0.87 suggests lower market correlation, but it is not immune to sector rotation or macro headwinds. The forward P/E of 19.3x implies aggressive earnings growth expectations; if the broader market reprices growth stocks due to rising rates or recession fears, TMO could suffer. Competitive risks include pricing pressure from rivals like Danaher and Agilent, though Thermo Fisher's scale and diversified portfolio provide a moat. Recent news about 'modest inflation' risk from Middle East tensions highlights geopolitical vulnerability that could disrupt supply chains or raise input costs.
Worst-Case Scenario: In a severe downturn where biopharma funding dries up and revenue growth turns negative, the stock could retest its 52-week low of $403.36, representing a -23.5% decline from the current price of $527.05. If margins compress to 2024 levels (net margin ~15%) and the P/E contracts to 25x (still above industry average), the stock could fall to ~$450, a -14.6% loss. The max drawdown of -31.45% from the 52-week high suggests that in a worst-case scenario, an investor could lose up to 31% from peak, or about 23% from current levels.
FAQ
The key risks are: 1) Valuation risk: trailing P/E of 32.6x leaves little room for error; a 10% earnings miss could lead to a 15-20% price decline. 2) Macro risk: a recession could reduce biopharma and academic research spending, slowing revenue growth below 4%. 3) Inflation risk: management flagged 'modest inflation' from Middle East tensions, which could compress margins if input costs rise. 4) Competitive risk: rivals like Danaher and Agilent could intensify pricing pressure, though TMO's scale provides a buffer. The most severe risk is a combination of slowing growth and multiple compression, which could drive the stock to the 52-week low of $403, a -23.5% decline from current levels.
The 12-month forecast for TMO is balanced across three scenarios. The base case (50% probability) assumes 5-6% revenue growth and stable margins, yielding a price range of $550-$650, with the analyst average target of ~$729 as an upside stretch. The bull case (25% probability) sees revenue acceleration to 8-10% and margin expansion above 20%, pushing the stock to $650-$750. The bear case (25% probability) envisions growth deceleration to 2-3% and margin compression, driving the stock to $400-$500, near the 52-week low of $403. The most likely scenario is the base case, where the stock trades in the $550-$650 range, offering modest upside from current levels.
TMO's trailing P/E of 32.6x is above the industry average of ~25x, indicating a premium valuation. However, the forward P/E of 19.3x implies that the market expects significant earnings growth, which could justify the premium if realized. Historically, the trailing P/E has ranged from 19x to 43x over the past five years, so the current level is near the middle of that range, suggesting it is fairly valued relative to its own history. The PEG ratio of 4.54x, however, indicates the stock is expensive relative to its growth rate, implying that growth expectations are already priced in. Overall, TMO is fairly valued to slightly overvalued, and investors should not expect multiple expansion from here.
TMO is a good stock to buy for long-term investors seeking quality exposure to life sciences, but the current price of $527 offers a mixed risk/reward. The analyst consensus is 'Buy' with an average target of ~$729, implying +38% upside, but the trailing P/E of 32.6x is above the industry average of ~25x, suggesting limited margin of safety. The biggest downside risk is multiple compression if growth disappoints, which could push the stock to $450 or lower. For new investors, it may be better to wait for a pullback to the $450-500 range, where the valuation becomes more attractive. Existing holders can continue to hold given the improving fundamentals and strong cash flow.
TMO is best suited for long-term investment (3-5 years) given its stable growth profile, strong cash flows, and dominant market position. The beta of 0.87 indicates lower volatility than the market, making it a defensive growth holding. The dividend yield is low at 0.29%, so income-seeking investors may look elsewhere. Short-term trading is less attractive due to the stock's modest near-term upside potential and the risk of multiple compression. A concrete suggested minimum holding period is 3 years, allowing time for the earnings growth to catch up to the valuation. For patient investors, TMO can serve as a core portfolio holding in the healthcare sector.